Status:

COMPLETED

Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children

Lead Sponsor:

University of Oxford

Collaborating Sponsors:

Mahidol Oxford Tropical Medicine Research Unit

Conditions:

Plasmodium Falciparum

Eligibility:

All Genders

2-12 years

Phase:

PHASE3

Brief Summary

This open-label randomised controlled clinical trial will compare the safety, tolerability, therapeutic efficacy and pharmacokinetics and pharmacodynamics of arterolane-piperaquine, arterolane-piperaq...

Eligibility Criteria

Inclusion

  • Male or female aged 2 years to \<13-year-old
  • Uncomplicated falciparum malaria as defined as:
  • Positive blood smear with asexual forms of P. falciparum (may be mixed with non-falciparum species)
  • Parasitaemia between 5,000-250,000 parasites/µL
  • Fever defined as tympanic temperature \>37.5°C or history of fever within last 48 hours
  • Ability to take oral medication
  • Willingness and ability to comply with study protocol for study duration
  • Written informed consent given to participate in the trial

Exclusion

  • Signs of severe/complicated malaria\*
  • Any clinical reason suggesting that the child's treatment should be given immediately and not delayed during the transfer to Kilifi County Hospital in the opinion of the treating physician.
  • Acute illness other than malaria requiring urgent systemic treatment as assessed by the treating physician
  • Previous splenectomy
  • Treatment with artemisinin or ACT within the previous 7 days
  • Treatment with mefloquine in the 2 months prior to presentation
  • Known hypersensitivity or contraindication to arterolane-piperaquine, DHA-piperaquine, artemisinin, mefloquine (epilepsy, major psychiatric illness) or primaquine
  • QTc interval \>450 milliseconds at point of presentation
  • Known personal or family history of cardiac conduction problems
  • Participation within another clinical trial in the previous 3 months

Key Trial Info

Start Date :

March 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 3 2019

Estimated Enrollment :

219 Patients enrolled

Trial Details

Trial ID

NCT03452475

Start Date

March 7 2018

End Date

June 3 2019

Last Update

September 29 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kilifi County Hospital

Kilifi, Kenya, P.O Box P.O. Box 9